ApoE2 Exaggerates PTSD-Related Behavioral, Cognitive, and Neuroendocrine Alterations

Lance A. Johnson, Damian G. Zuloaga, Erin Bidiman, Tessa Marzulla, Sydney Weber, Helane Wahbeh, Jacob Raber

Research output: Contribution to journalArticlepeer-review

53 Scopus citations

Abstract

Apolipoprotein E (apoE) is an essential component of lipoprotein particles in both the brain and periphery, and exists in three isoforms in the human population: E2, E3, and E4. ApoE has numerous, well-established roles in neurobiology. Most notably, E4 is associated with earlier onset and increased risk of Alzheimer's disease (AD). Although possession of E2 is protective in the context of AD, E2 appears to confer an increased incidence and severity of posttraumatic stress disorder (PTSD). However, the biological processes underlying this link remain unclear. In this study, we began to elucidate these associations by examining the effects of apoE on PTSD severity in combat veterans, and on PTSD-like behavior in mice with human apoE. In a group of 92 veterans with PTSD, we observed significantly higher Clinician-Administered PTSD Scale and PTSD Checklist scores in E2+ individuals, as well as alterations in salivary cortisol levels. Furthermore, we measured behavioral and biological outcomes in mice expressing human apoE after a single stressful event as well as following a period of chronic variable stress, a model of combat-related trauma. Mice with E2 showed impairments in fear extinction, and behavioral, cognitive, and neuroendocrine alterations following trauma. To the best of our knowledge, these data constitute the first translational demonstration of PTSD severity in men and PTSD-like symptoms in mice with E2, and point to apoE as a novel biomarker of susceptibility, and potential therapeutic target, for PTSD.

Original languageEnglish
Pages (from-to)2443-2453
Number of pages11
JournalNeuropsychopharmacology
Volume40
Issue number10
DOIs
StatePublished - Sep 14 2015

Bibliographical note

Publisher Copyright:
© 2015 American College of Neuropsychopharmacology. All rights reserved.

Funding

LAJ was supported by NIEHS Grant T32-ES07060, NIH Grant T32-HL094294, and NSF Postdoctoral Fellowship SMA-1408653. HW was supported by NIH Grant K01AT004951.The content of this manuscript is solely the responsibility of the authors and do not necessarily represent the official views of the NIH or NSF. EB was supported by a Miller Fellowship through Lewis and Clark College, Portland, OR. The authors declare no conflict of interest.

FundersFunder number
National Institutes of Health/National Institute of Environmental Health Sciences
National Institutes of Health (NIH)K01AT004951
National Science Foundation Arctic Social Science Program
National Science Foundation Arctic Social Science ProgramSMA-1408653
National Science Foundation Arctic Social Science Program
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)T32HL094294
National Heart, Lung, and Blood Institute (NHLBI)
National Institutes of Health/National Institute of Environmental Health SciencesT32-ES07060
National Institutes of Health/National Institute of Environmental Health Sciences

    ASJC Scopus subject areas

    • Pharmacology
    • Psychiatry and Mental health

    Fingerprint

    Dive into the research topics of 'ApoE2 Exaggerates PTSD-Related Behavioral, Cognitive, and Neuroendocrine Alterations'. Together they form a unique fingerprint.

    Cite this